SPC365

Impact of Cancer Therapies on Atrial Fibrillation: Incidence, Risk Factors, and Clinical Implications

Session: SESSÃO DE POSTERS 29 - FIBRILHAÇÃO AURICULAR: DA PREVENÇÃO À INTERVENÇÃO
Speaker: Nuno Alexandre Dias Madruga

Congress: CPC 2025
Topic: K. Cardiovascular Disease In Special Populations
Theme: 30. Cardiovascular Disease in Special Populations
Subtheme: 30.6 Cardio-Oncology
Session Type: Cartazes
FP Number: ---
Authors: Nuno Madruga; Andreia Magalhães; Catarina Gregório; Miguel Azaredo Raposo; Ana Abrantes; Diogo Rosa Ferreira; Marta Vilela; Inês Caldeira Araújo; Catarina Sena da Silva; Miguel Nobre Menezes; Manuela Fiúza; Fausto J. Pinto

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><strong><span style="font-family:&quot;Calibri&quot;,sans-serif">Introduction:</span></strong></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="font-family:&quot;Calibri&quot;,sans-serif">Atrial fibrillation (AF) is a common arrhythmia associated with significant morbidity and mortality. Cancer therapies, while improving survival rates, are increasingly recognized as contributing to cardiac toxicity and to the development of AF. </span></span></span></p>

<p style="text-align:justify">&nbsp;</p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><strong><span style="font-family:&quot;Calibri&quot;,sans-serif">Purpose: </span></strong></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="font-family:&quot;Calibri&quot;,sans-serif">To investigate the incidence, risk factors, and clinical implications of AF induced by cancer therapies.</span></span></span></p>

<p style="text-align:justify">&nbsp;</p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><strong><span style="font-family:&quot;Calibri&quot;,sans-serif">Methods: </span></strong></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="font-family:&quot;Calibri&quot;,sans-serif">A retrospective, single-center, observational study was conducted, including patients seen in a cardio-oncology consultation at a tertiary university hospital between 2022 and 2023. Statistical analyses were performed using parametric and non-parametric tests.</span></span></span></p>

<p style="text-align:justify">&nbsp;</p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><strong><span style="font-family:&quot;Calibri&quot;,sans-serif">Results:</span></strong></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="font-family:&quot;Calibri&quot;,sans-serif">A total of 185 patients (48% male, mean age 64 &plusmn; 15 years) were included. Of these, 22 patients had previous AF (12%). During follow-up, 17 patients (9.2%) developed AF after initiating cancer treatment (prevalence of 9,1%). Patients who developed AF were older with a mean age of 71&plusmn;11 versus 64&plusmn;15 years&nbsp; in patients without AF (p=0.057). The most prevalent comorbidities amongst this group of patients were arterial hypertension (64.7%), dyslipidemia (35.3%), diabetes (17.6%) and chronic kidney disease (17.6%). There was no statistical association between comorbidities and new-onset AF. Regarding cancer therapies, 47.1% underwent target therapy, 41.7% hormone therapy, 35.3% of patients chemotherapy and 35.3% radiotherapy. Hormone therapy was highly associated with the development of AF (p=0.022). There was no statistical association with other types of cancer therapy and new-onset AF. During a mean follow-up time of 15.9 &plusmn; 9.3 months, 23.5% of patients with new-onset AF had at least one hospitalization for cardiovascular causes versus 10.1% of patients without AF (p=0.097). However, this did not translate into an increase in mortality (p=0.932). Amongst the 17 patients with new-onset AF, 16 initiated anticoagulation. This was not related to an increase in hemorrhagic complications (p=0.797).</span></span></span></p>

<p style="text-align:justify">&nbsp;</p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><strong><span style="font-family:&quot;Calibri&quot;,sans-serif">Conclusion:</span></strong></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="font-family:&quot;Calibri&quot;,sans-serif">New-onset AF is a common event in patients undergoing cancer therapies, particularly hormone therapy. Although AF did not increase mortality, it was associated with higher hospitalization rates for cardiovascular causes. These findings emphasize the need for proactive cardiovascular monitoring and management in cancer patients to reduce AF-related complications and improve overall outcomes.</span></span></span></p>